Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Multicenter Study to Assess the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Complement Inhibitor Treatment Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China

NCT05886244 is registered in ClinicalTrials.gov with Alexion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05886244
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05886244 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Multicenter Study to Assess the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Complement Inhibitor Treatment Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China
Lead sponsor
Alexion Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
July 5, 2023
Completion date
April 14, 2025
Enrollment
25 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

paroxysmal nocturnal hemoglobinuria